Next-Generation Molecular Imaging of Thyroid Cancer

Jin, Yuchen; Liu, Beibei; Younis, Muhsin H.; Huang, Gang; Li, Jianjun; Cai, Weibo; Wei, Weijun

doi:10.3390/cancers13133188

Cited by 7 publications

(5 citation statements)

References 171 publications

(263 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrast Media & Molecular Imaging employed in the early diagnosis and treatment of malignancies, plays a significant role in the process of tumor metastasis [14,15]. Pertuzumab is used as a targeted substance for specific binding with HER2, which can achieve specific binding with HER2 receptor on the surface of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Preparation and MRI Study of HER2‐Targeted Bimodal Molecular Probe Gd‐Cy5.5‐Pertuzumab for Thyroid Cancer

Tian

Liu

Xie

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Purpose. A bimodal nanoprobe for thyroid cancer targeting human epidermal growth factor receptor 2 (HER2) was synthesized by coupling the magnetic resonance contrast agent Gd3+ with the fluorescent dyes Cy5.5 and pertuzumab as a preliminary study of Gd-Cy5.5-pertuzumab in magnetic resonance and fluorescence imaging. Methods. The bifunctional chelate p-SCN-Bn-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic-acid (DOTA) was dissolved in deionized water, added to pertuzumab solution, and stirred overnight at room temperature to obtain the product DOTA pertuzumab. 1,2-dichloroethane and N-hydroxysuccinimide were added to activate the carboxyl group on DOTA. After 0.5 hr of activation, the amino fluorescent dye Cy5.5 was further added to react with it to synthesize the intermediate product Cy5.5-DOTA-pertuzumab. Finally, we added GdCl3-6H2O and placed it in a magnetic stirrer for 6 hr before the unreacted substance was removed by dialysis to obtain Gd-Cy5.5-pertuzumab. Following that, the hydrated particle size and zeta potential of the nanoprobe were measured by particle size analyzer, the fluorescence spectrum by a fluorescence detector, the infrared spectrum by the infrared analyzer, the cytotoxicity by CCK-8 method, the relaxation rate by Niumai small nuclear magnetic field, and the binding ability of HER2 to thyroid cancer 8505C by laser confocal microscope. Nanoprobes were injected into a subcutaneous thyroid cancer nude mouse model through the tail vein, and in vivo MRI and near-infrared (NIR) fluorescence imaging were performed. Finally, the nude mice were dissected and hematoxylin and eosin (HE) staining of pathological tissues was performed to evaluate the imaging performance of the prepared bimodal probes. Results. The synthesized bimodal probe Gd-Cy5.5-pertuzumab had a hydrodynamic size of 131.34 ± 9.43 nm and zeta potential of −31.73 ± 6.24 mV with a significant absorption peak at 685 nm. The relaxation rate of the probe was 46.53 mM−1 s−1, which was determined by Niumai small nuclear magnetism, and the T1 signal intensity increased gradually with the concentration of the probe. Laser confocal microscopy showed that HER2 was mainly expressed in cell membranes. In vitro and in vivo experiments indicated that the probe had low cytotoxicity. MRI and small animal fluorescence imaging of tumor-bearing nude mice showed that the probe could clearly image tumor tissue. Conclusion. The bimodal probe Gd-Cy5.5-pertuzumab was successfully synthesized with good stability, which can specifically bind to target cells in vivo and has good magnetic resonance/fluorescence imaging performance.

show abstract

Section: Discussionmentioning

confidence: 99%

Preparation and MRI Study of HER2‐Targeted Bimodal Molecular Probe Gd‐Cy5.5‐Pertuzumab for Thyroid Cancer

Tian

Liu

Xie

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…Changes in the expression of functional tumor biomarkers may occur earlier than changes in lesion size as assessed by conventional morphological imaging 126 . In recent decades, molecular nuclear medicine imaging, especially immunoPET imaging, has become an increasingly popular approach to help clinicians locate biomarkers and potential therapeutic targets 128 . Specific and highly expressed biomarkers are expected to be the potential targets of immunePET imaging.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

“…126 In recent decades, molecular nuclear medicine imaging, especially immunoPET imaging, has become an increasingly popular approach to help clinicians locate biomarkers and potential therapeutic targets. 128 Specific and highly expressed biomarkers are expected to be the potential targets of immunePET imaging. One of the histological hallmark features of PDAC is the pronounced TME that dynamically evolves in the process of tumor progression.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Molecular imaging of pancreatic ductal adenocarcinoma

Huang

et al. 2023

VIEW

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), a deadly cancer characterized by multiple molecular alterations, remains the most lethal cancer, with a 5‐year survival rate of about 3–15%. Early diagnosis and treatment monitoring are essential to improve patient survival. Traditional imaging methods can only provide structural information, but not biological processes. Nuclear medicine imaging combines the high sensitivity of radionuclides with high‐resolution structural imaging to visualize specific targets of PDAC for more accurate and reliable diagnosis and monitoring of therapeutic responses. In this review, we summarize the available literature regarding molecular nuclear medicine imaging in PDAC. We classify the probe targets into two categories, targeting tumor cell membranous and the tumor microenvironment, respectively. We summarize the latest evidence in this field and outline how these emerging strategies could potentially optimize clinical practice.

show abstract

“…However, management of less common thyroid cancer subtypes is challenging. Recently, various molecules were evaluated for targeted imaging and therapy in these cancers ( 274 , 275 ).…”

Section: Immunopet In Different Malignanciesmentioning

confidence: 99%

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

et al. 2022

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target a broad spectrum of molecules expressed by malignant cells or tumor microenvironments. Only a few are translated into clinical studies and barely into clinical practices. Some drawbacks include slow radioimmunotracer kinetics, high physiologic uptake in lymphoid organs, and heterogeneous activity in tumoral lesions. Measures are taken to overcome the disadvantages, and new tracers are being developed. In this review, we aim to mention the fundamental components of immunoPET imaging, explore the groundbreaking success achieved using this new technique, and review different radioimmunotracers employed in various solid tumors to elaborate on this relatively new imaging modality.

show abstract

Next-Generation Molecular Imaging of Thyroid Cancer

Cited by 7 publications

References 171 publications

Preparation and MRI Study of HER2‐Targeted Bimodal Molecular Probe Gd‐Cy5.5‐Pertuzumab for Thyroid Cancer

Preparation and MRI Study of HER2‐Targeted Bimodal Molecular Probe Gd‐Cy5.5‐Pertuzumab for Thyroid Cancer

Molecular imaging of pancreatic ductal adenocarcinoma

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Contact Info

Product

Resources

About